FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Merck known as MSD outside of the United States and Canada, announced that…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer AstraZeneca’s IMFINZI® in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the…
Hexcel, NIAR Break Ground on New Hexcel Applications Center at Wichita State University Hexcel Corporation a global leader in advanced composite materials, announced the groundbreaking of the Hexcel Applications Center at Wichita State University’s National Institute for Aviation Research (NIAR).…
Graco Foundation Marks Company’s Centennial with $1 Million Commitment to Minnesota Nonprofits In celebration of Graco’s 100th anniversary, the Graco Foundation announced a $1 million Centennial Impact Initiative to support 10 Minnesota nonprofit organizations advancing self-sufficiency, stability and workforce development,…
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation ICON plc a world-leading clinical research organization, reported its financial results for the fourth quarter and full year 2025, and announced the outcome of its…
Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30…
Wolters Kluwer and Radiological Society of North America Establish 10-Year Agreement to Advance Global Access to Leading Radiology Research Journals Wolters Kluwer Health announced a new 10-year agreement to publish the Radiological Society of North America (RSNA) portfolio of five specialty journals…
Hepta’s Blood Test Outperforms FIB-4, ELF, and FibroScan in Identifying Treatment-Eligible MASH Patients Hepta, a liquid biopsy company developing blood tests for chronic disease, announced clinical data showing its blood test more accurately identifies metabolic dysfunction-associated steatohepatitis (MASH) patients eligible…
Archeus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer Archeus Technologies, a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers,…
Polar Semiconductor and Nexperia Partner on Power MOSFET Manufacturing to Strengthen Global Supply Polar Semiconductor, LLC and Nexperia B.V. announced a strategic collaboration to manufacture next‑generation power MOSFET devices at Polar Semiconductor’s U.S.‑based wafer foundry. The partnership supports an expanded…
Inbolt Launches Vision-Enabled Robot Programming, Closing the Loop from CAD to Factory Floor Inbolt, the robot intelligence company that turns digital twins into live robot control, is launching two new capabilities that complete the company’s AI vision model for robot guidance:…
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model Turn Therapeutics Inc. a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, announced the publication of…